HPV Vaccine Significantly Reduces Cancer Risk in Young Males, Study Shows Vaccinating boys and young men against human papillomavirus (HPV) substantially lowers their risk of developing HPV-related cancers, according to recent research. A large-scale cohort study published in JAMA Oncology found that males who received the nine-valent HPV vaccine had approximately half the risk of HPV-associated cancers compared to their unvaccinated peers. The study analyzed health data from over 615,000 vaccinated males, and 2.29 million unvaccinated males aged 9 to 26 years. Researchers evaluated the incidence of HPV-related cancers, including head and neck (oropharyngeal), anal, and penile cancers. Results showed a marked reduction in cancer risk among vaccinated individuals, with an overall hazard ratio of 0.54, indicating a 46% lower risk. Protection varied slightly by age at vaccination. Males vaccinated between ages 9 and 14 had a 42% lower risk of HPV-related cancers (hazard ratio 0.58), while those vaccinated between ages 15 and 26 experienced a 50% reduction in risk (hazard ratio 0.50). These findings support the effectiveness of the vaccine even when administered during adolescence or young adulthood. HPV is a common viral infection that can lead to several types of cancer in both men and women. While vaccination efforts initially focused on preventing cervical cancer in women, the virus too causes significant health burdens in males. Oropharyngeal cancer, in particular, has been rising among men and is often diagnosed at later stages, complicating treatment. Experts emphasize that vaccinating boys is essential not only for individual protection but also for reducing community transmission. Since HPV often causes no symptoms, infected individuals can unknowingly spread the virus. Expanding vaccination programs to include males helps close this gap in prevention and supports broader public health goals. The nine-valent HPV vaccine protects against nine strains of the virus, including those most strongly linked to cancer. Health authorities recommend routine HPV vaccination for all adolescents starting at age 11 or 12, with catch-up vaccination available for individuals through age 26 who were not adequately vaccinated earlier. These findings reinforce the value of sex-neutral HPV vaccination strategies in reducing cancer incidence across populations. By preventing infection with high-risk HPV strains, the vaccine offers a powerful tool for lowering the long-term burden of HPV-associated cancers in men.
40